Claims for Patent: 10,226,550

Summary for Patent: 10,226,550

Title:	Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
Abstract:	This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.
Inventor(s):	Savage; Paul B. (Mapleton, UT), Genberg; Carl (Las Vegas, NV), Bracken; Ronald (Monroe, GA)
Assignee:	BRIGHAM YOUNG UNIVERSITY (Provo, UT)
Application Number:	15/454,135
Patent Claims:	1. A soft tissue filler composition for injection into soft tissue, comprising: a biologically compatible soft tissue filler material in the form of a liquid, gel, paste, or viscous material so as to be syringe-injectable into soft tissue at a treatment site, wherein the soft tissue filler composition comprises a tissue adhesive; and 0.1% to 30% (w/w) of one or more cationic steroidal antimicrobial (CSA) compounds incorporated into the biologically compatible soft tissue filler material so that, when injected into soft tissue, the soft tissue filler material can form a bolus having a reservoir of CSA compounds incorporated into and distributed within a matrix of the soft tissue filler material and provide effective time release of the one or more CSA compounds from the soft tissue filler material. 2. The soft tissue filler composition of claim 1, wherein the tissue adhesive comprises cyanoacrylate. 3. The soft tissue filler composition of claim 2, wherein the tissue adhesive includes an octyl or butyl ester of cyanoacrylate. 4. The soft tissue filler composition of claim 1, wherein the soft tissue filler material comprises one or more syringe-injectable bioabsorbable materials. 5. The soft tissue filler composition of claim 1, wherein the soft tissue filler material comprises one or more of hyaluronic acid, collagen, hydroxyapatite mineral, or poly-l-lactic acid in syringe-injectable form. 6. The soft tissue filler composition of claim 1, wherein the soft tissue filler material comprises one or more of silicone or polymethylmethacrylate in syringe-injectable form. 7. The soft tissue filler composition of claim 1, wherein the soft tissue filler composition comprises botox. 8. The soft tissue filler composition of claim 1, wherein the one or more CSA compounds are included in the soft tissue filler composition in an amount ranging from about 0.5% to about 20% (w/w). 9. The soft tissue filler composition of claim 1, wherein the one or more CSA compounds independently provide to the soft tissue filler composition at least one of anti-microbial effect, anti-inflammatory effect, or increased rate of tissue wound healing. 10. The soft tissue filler composition of claim 1, wherein the one or more CSA compounds includes CSA-131. 11. The soft tissue filler composition of claim 1, wherein the one or more CSA compounds includes one or more sulfonic acid addition salts. 12. The soft tissue filler composition of claim 11, wherein the one or more sulfonic acid addition salts includes 1,5-naphthalenedisulfonic acid salt. 13. The soft tissue filler composition of claim 1, wherein the soft tissue filler composition provides protection against biofouling longer than a soft tissue filler composition not having one or more incorporated CSA compounds. 14. The soft tissue filler composition of claim 1, wherein the soft tissue filler composition provides enhanced anti-inflammatory activity as compared to a soft tissue filler composition not having one or more incorporated CSA compounds. 15. A method for controlling microbial growth on an injected soft tissue filler composition and/or at a treatment site at which the soft tissue filler composition has been injected, comprising: providing a syringe-injectable soft tissue filler composition in the form of a liquid, gel, paste, or viscous material and comprising a biologically compatible soft tissue filler material and 0.1% to 30% (w/w) of one or more cationic steroidal antimicrobial (CSA) compounds incorporated into the soft tissue filler material, wherein the soft tissue filler composition is a tissue glue, and wherein the tissue glue is injected so as to embolize a blood vessel or occlude a fistula; injecting the soft tissue filler composition by syringe into soft tissue at the treatment site; and the one more CSA compounds killing one or more microbes contacting the soft tissue filler composition. 16. The method of claim 15, wherein the one or more CSA compounds include CSA-131, and wherein the CSA-131 is provided as a sulfonic acid addition salt. 17. The method of claim 15, wherein the syringe-injectable soft tissue filler comprises one or more of a bioabsorbable material, hyaluronic acid, collagen, hydroxyapatite mineral, poly-l-lactic acid, or silicone. 18. A method for controlling microbial growth at a wound site, comprising: providing a tissue adhesive composition comprising a biologically compatible cyanoacrylate adhesive material and one or more cationic steroidal antimicrobial (CSA) compounds incorporated into the cyanoacrylate adhesive material; injecting and/or applying the tissue adhesive composition onto tissue at the wound site so as to close a wound, embolize a blood vessel, or occlude a fistula; and the tissue adhesive composition killing one or more microbes contacting the tissue adhesive composition. 19. The method of claim 18, wherein the one or more CSA compounds comprise a 1,5-naphthalenedisulfonic acid salt of CSA-131.

Details for Patent 10,226,550

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	BOTOX COSMETIC	onabotulinumtoxina	For Injection	103000	December 09, 1991	10,226,550	2036-03-11
Abbvie Inc.	BOTOX	onabotulinumtoxina	For Injection	103000	December 09, 1991	10,226,550	2036-03-11